- Prospective, randomized, international multicenter study - PACE - Prostate Advances in Comparative Evidence - results presented at ESTRO 2021 - Bladder side effects were experienced half as often with CyberKnife SBRT as with conventional linear accelerator delivered SBRT two years after treatment
SUNNYVALE, Calif. , Aug. 23, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Mika Nishimura to the company's Board of Directors, effective as of August 17, 2021 . With Ms. Nishimura's appointment, the Accuray Board will consist of nine members. Ms.
Accuray develops, manufactures and sells radiation oncology systems that make cancer treatments shorter, safer, smarter and more effective. Accuray provides treatment delivery technologies that set the industry standard for precision and cover the full range of radiation therapy and radiosurgery treatments, as well as fully integrated software solutions that drive faster, smarter treatment planning.